EHC
Encompass Health Corporation NYSE$107.48
Mkt Cap $11.0B
52w Low $92.77
41.8% of range
52w High $127.99
50d MA $103.42
200d MA $111.52
P/E (TTM)
19.1x
EV/EBITDA
9.5x
P/B
3.3x
Debt/Equity
1.1x
ROE
23.2%
P/FCF
24.3x
RSI (14)
—
ATR (14)
—
Beta
0.60
50d MA
$103.42
200d MA
$111.52
Avg Volume
1.1M
About
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 1.51 | 1.60 | +6.0% | 100.00 | +1.4% | +7.5% | — | — | — | — | — | — |
| Feb 5, 2026 | AMC | 1.29 | 1.46 | +13.2% | 99.56 | +15.5% | +5.9% | +6.6% | +9.5% | +13.9% | +12.6% | +9.1% | — |
| Oct 29, 2025 | AMC | 1.19 | 1.23 | +3.4% | 125.63 | -9.9% | -7.0% | -9.4% | -7.6% | -6.8% | -8.2% | -7.5% | — |
| Aug 4, 2025 | AMC | 1.23 | 1.40 | +13.8% | 109.50 | +1.9% | +4.0% | +6.4% | +6.4% | +7.4% | +7.3% | +12.9% | — |
| Apr 24, 2025 | AMC | 1.19 | 1.37 | +15.1% | 101.41 | +9.9% | +11.8% | +13.7% | +14.3% | +15.4% | +14.3% | +19.3% | — |
| Feb 6, 2025 | AMC | 1.05 | 1.17 | +11.4% | 98.60 | +3.8% | +1.3% | +0.0% | +0.8% | -0.6% | +1.6% | +0.5% | — |
| Oct 28, 2024 | AMC | 0.94 | 1.03 | +9.6% | 93.09 | +8.0% | +7.4% | +8.9% | +6.8% | +6.3% | +7.7% | +10.5% | — |
| Aug 5, 2024 | AMC | 1.01 | 1.11 | +9.9% | 89.67 | -3.9% | -5.6% | -5.2% | -2.9% | -4.4% | -3.1% | +4.4% | — |
| Apr 24, 2024 | AMC | 0.94 | 1.12 | +19.1% | 82.80 | +3.0% | -0.1% | -0.4% | +1.0% | +0.7% | +0.1% | +2.0% | — |
| Feb 7, 2024 | AMC | 0.82 | 0.95 | +15.9% | 72.76 | +1.0% | +0.9% | +0.2% | +1.1% | +0.4% | +0.8% | +5.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6 | Barclays | Maintains | Overweight → Overweight | — | $99.56 | $115.00 | +15.5% | +5.9% | +6.6% | +9.5% | +13.9% | +12.6% |
| Oct 30 | Barclays | Maintains | Overweight → Overweight | — | $125.63 | $113.18 | -9.9% | -7.0% | -9.4% | -7.6% | -6.8% | -8.2% |
| Oct 2 | UBS | Maintains | Buy → Buy | — | $124.52 | $125.00 | +0.4% | -0.8% | -1.0% | -0.7% | +0.5% | -0.1% |
| Sep 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $124.66 | $124.88 | +0.2% | -0.7% | -0.3% | +0.5% | -0.5% | +1.1% |
| Sep 10 | BofA Securities | Maintains | Buy → Buy | — | $125.29 | $125.24 | -0.0% | -0.6% | +1.2% | +0.6% | -0.5% | -1.2% |
| Aug 14 | Truist | Maintains | Buy → Buy | — | $119.13 | $119.30 | +0.1% | +0.4% | +1.0% | +0.9% | +2.5% | +3.7% |
| Aug 6 | UBS | Maintains | Buy → Buy | — | $113.88 | $114.43 | +0.5% | +2.3% | +2.3% | +3.2% | +3.1% | +4.2% |
| Jun 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $121.27 | $121.81 | +0.4% | +0.0% | +0.2% | -0.8% | -1.7% | -1.5% |
| May 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $118.90 | $119.74 | +0.7% | +1.8% | +0.5% | +0.9% | +1.7% | +1.6% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $113.37 | $113.44 | +0.1% | +1.7% | +2.2% | +3.2% | +2.3% | +2.9% |
Recent Filings
8-K
Unknown — 8-K Filing
The merger is progressing on schedule with regulatory approval secured, suggesting the deal will close in Q2 2026 as planned, reducing execution risk for shareholders awaiting the transaction completion.
Apr 16
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
EHC terminated its credit facility with Barclays, signaling either refinancing with better terms or reduced borrowing needs, which could improve financial flexibility and reduce debt costs going forward.
Mar 10
8-K · 5.02
!!! Very High
Encompass Health Corporation -- 8-K 5.02: Executive Change
Encompass Health Corporation appointed a new director, Mr. Hayes, signaling potential strategic shifts or governance changes that investors should monitor for impact on company direction.
Feb 20
8-K · 5.02
!!! Very High
Norwegian Cruise Line Holdings Ltd. -- 8-K 5.02: Executive Change
Norwegian Cruise Line Holdings appointed John W. Chidsey as President, a leadership change that may signal strategic direction shifts for the cruise operator's operational and growth initiatives.
Feb 12
8-K · 5.02
!!! Very High
NCL CORP Ltd. -- 8-K 5.02: Executive Change
Norwegian Cruise Line Holdings appointed John W. Chidsey as President, signaling potential strategic leadership changes that investors should monitor for operational and financial direction shifts.
Feb 12
8-K · 7.01
! Medium
Encompass Health Corporation -- 8-K 7.01: Regulation FD Disclosure
Encompass Health disclosed non-material information under Regulation FD that won't be legally incorporated into SEC filings unless explicitly referenced elsewhere.
Feb 5
8-K · 5.02
!!! Very High
Encompass Health Corporation -- 8-K 5.02: Executive Change
Encompass Health Corporation appointed Cain A. Hayes as a director, adding new board representation that could influence governance and strategic decisions for the healthcare services provider.
Feb 2
Data updated apr 25, 2026 6:42am
· Source: massive.com